Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON

por Lorenzatti, Alberto J., Monsalvo, Maria Laura, López, J. Antonio G., Wang, Huei, Rosenson, Robert S.
Publicado 2021

Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies

por May, Heidi T., Muhlestein, Joseph B., Ma, Yuhui, López, J. Antonio G., Coll, Blai, Nelson, John
Publicado 2019

Evolocumab Effects on Lipoproteins, Measured by High-Performance Liquid Chromatography

por Masuda, Daisaku, Kiyosue, Arihiro, Hirayama, Atsushi, Shimauchi, Junichiro, López, J. Antonio G., Miyawaki, Kazumasa, Yamashita, Shizuya
Publicado 2020

Effect of Evolocumab on Non‐High‐Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies

por Toth, Peter P., Jones, Steven R., Monsalvo, Maria Laura, Elliott‐Davey, Mary, López, J. Antonio G., Banach, Maciej
Publicado 2020

Effects of Evolocumab on Low‐Density Lipoprotein Cholesterol, Non–High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta‐Analysis...

por Daviglus, Martha L., Ferdinand, Keith C., López, J. Antonio G., Wu, You, Monsalvo, Maria Laura, Rodriguez, Carlos J.
Publicado 2020

Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population

por Li, Suying, Peng, Yi, Wang, Xinyue, Qian, Yi, Xiang, Pin, Wade, Sally W., Guo, Haifeng, Lopez, J. Antonio G., Herzog, Charles A., Handelsman, Yehuda
Publicado 2019

A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies

por Koren, Michael J., Jones, Peter H., Robinson, Jennifer G., Sullivan, David, Cho, Leslie, Hucko, Thomas, Lopez, J. Antonio G., Fleishman, Alex N., Somaratne, Ransi, Stroes, Erik
Publicado 2020

Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease

por Colantonio, Lisandro D., Bittner, Vera, Safford, Monika M., Marcovina, Santica, Brown, Todd M., Jackson, Elizabeth A., Li, Mei, López, J. Antonio G., Monda, Keri L., Plante, Timothy B., Kent, Shia T., Muntner, Paul, Rosenson, Robert S.
Publicado 2022

Cardiovascular outcomes in patients with coronary artery disease and elevated lipoprotein(a): implications for the OCEAN(a)-outcomes trial population

por Shiyovich, Arthur, Berman, Adam N, Besser, Stephanie A, Biery, David W, Huck, Daniel M, Weber, Brittany, Cannon, Christopher, Januzzi, James L, Booth, John N, Nasir, Khurram, Di Carli, Marcelo F, López, J Antonio G, Kent, Shia T, Bhatt, Deepak L, Blankstein, Ron
Publicado 2023

Ancestral diversity in lipoprotein(a) studies helps address evidence gaps

por Lee, Moa P, Dimos, Sofia F, Raffield, Laura M, Wang, Zhe, Ballou, Anna F, Downie, Carolina G, Arehart, Christopher H, Correa, Adolfo, de Vries, Paul S, Du, Zhaohui, Gignoux, Christopher R, Gordon-Larsen, Penny, Guo, Xiuqing, Haessler, Jeffrey, Howard, Annie Green, Hu, Yao, Kassahun, Helina, Kent, Shia T, Lopez, J Antonio G, Monda, Keri L, North, Kari E, Peters, Ulrike, Preuss, Michael H, Rich, Stephen S, Rhodes, Shannon L, Yao, Jie, Yarosh, Rina, Tsai, Michael Y, Rotter, Jerome I, Kooperberg, Charles L, Loos, Ruth J F, Ballantyne, Christie, Avery, Christy L, Graff, Mariaelisa
Publicado 2023